-
Media ReleaseKymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
-
Media ReleaseAlcon Introduces AIR OPTIX® COLORS Contact Lenses Gemstone Collection, Creating New Ways to Enhance and Play with Eye Color
-
Media ReleaseNew Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
-
Media ReleaseNovartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
-
Media ReleaseAlcon teams up with Venus Williams, tennis champion and dry eye sufferer, to launch Systane® Complete eye drops
-
Media ReleaseNovartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
-
Media ReleaseFDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
-
Media ReleasePatient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
-
Media ReleaseNovartis and Amgen announce FDA approval of Aimovig™ (erenumab-aooe), a novel treatment developed specifically for migraine prevention
-
Media ReleaseNovartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
-
Media ReleaseNovartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
-
Media ReleaseThird Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer